Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 149 No. 3536 (2019)

The target uric acid level in multimorbid patients with gout is difficult to achieve: data from a longitudinal Swiss single-centre cohort

  • Barbara Ankli
  • Christoph T. Berger
  • Nicolas Haeni
  • Diego Kyburz
  • Thomas Hügle
  • Alexander K.-L. So
  • Thomas Daikeler
DOI
https://doi.org/10.4414/smw.2019.20121
Cite this as:
Swiss Med Wkly. 2019;149:w20121
Published
02.09.2019

Summary

OBJECTIVE

To characterise adherence and treat-to-target (T2T) strategy in gout patients within a Swiss tertiary hospital.

METHODS

Consecutive presenting patients with proven gout were prospectively included in this cohort. Symptoms, comorbidities, medication and laboratory values were assessed (during hospitalisation and at planned 3- and 12-month follow-up assessments).

RESULTS

116 patients (98 men) with a mean age of 67 (range 23–94 years) were included, 74% of whom had active arthritis. Comorbidities were frequent: hypertension, renal impairment, and obesity were present in 72, 55 and 35% of patients, respectively. Thirty-five percent of patients received urate-lowering treatment at inclusion. Only 62 and 50% attended the 3- and 12-month follow-up. The target serum uric acid level of <360 μmol/l was achieved in 22 and 57% of patients by the 3- and 12-month follow-up visits, respectively. Patients followed up by rheumatologists reached the target serum uric acid at follow-up more often than those that were not (p = 0.033). Median daily allopurinol dose at 12-month follow-up was 300 mg in those achieving T2T and 100 mg in the others (p = 0.033). Flares occurred during the first 3 months in 52% and during the subsequent 9 months in 47% of patients.

CONCLUSION

Only half of patients attended the planned follow-up visits, indicating low awareness for gout. Of those attending follow-up, only approximately 50% had achieved the serum urate target at 12 months. Although new treatments are available, care for gout patients remains insufficient, notably in difficult-to-treat multimorbid patient subsets as described in this cohort.

References

  1. Harris MD, Siegel LB, Alloway JA. Gout and hyperuricemia. Am Fam Physician. 1999;59(4):925–34.
  2. Landgren AJ, Jacobsson LTH, Lindström U, Sandström TZS, Drivelegka P, Björkman L, et al. Incidence of and risk factors for nephrolithiasis in patients with gout and the general population, a cohort study. Arthritis Res Ther. 2017;19(1):173. doi:.https://doi.org/10.1186/s13075-017-1376-z
  3. Ayoub I, Almaani S, Brodsky S, Nadasdy T, Prosek J, Hebert L, et al. Revisiting medullary tophi: a link between uric acid and progressive chronic kidney disease? Clin Nephrol. 2016;85(2):109–13. doi:.https://doi.org/10.5414/CN108663
  4. Iacobellis G, Iacobellis G. A rare and asymptomatic case of mitral valve tophus associated with severe gouty tophaceous arthritis. J Endocrinol Invest. 2004;27(10):965–6. doi:.https://doi.org/10.1007/BF03347542
  5. Khanna D, Tang S-J, Wallace WD, Roth BE, Hahn BH. Gouty tophi in a pancreatic pseudocyst. Arthritis Rheum. 2002;46(2):565–6. doi:.https://doi.org/10.1002/art.10067
  6. Neogi T, Jansen TLTA, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74(10):1789–98. doi:.https://doi.org/10.1136/annrheumdis-2015-208237
  7. Kuo C-F, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649–62. doi:.https://doi.org/10.1038/nrrheum.2015.91
  8. Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol. 2019;71(6):991–9. doi:.https://doi.org/10.1002/art.40807
  9. Krishnan E. Chronic kidney disease and the risk of incident gout among middle-aged men: a seven-year prospective observational study. Arthritis Rheum. 2013;65(12):3271–8. doi:.https://doi.org/10.1002/art.38171
  10. Mohammed E, Browne LD, Kumar AUA, Adeeb F, Fraser AD, Stack AG. Prevalence and treatment of gout among patients with chronic kidney disease in the Irish health system: A national study. PLoS One. 2019;14(1):e0210487. doi:.https://doi.org/10.1371/journal.pone.0210487
  11. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82(3):421–6. doi:.https://doi.org/10.1016/0002-9343(87)90441-4
  12. Scirè CA, Manara M, Cimmino MA, Govoni M, Salaffi F, Punzi L, et al.; KING Study Collaborators. Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR). Arthritis Res Ther. 2013;15(5):R101. doi:.https://doi.org/10.1186/ar4281
  13. Disveld IJM, Zoakman S, Jansen TLTA, Rongen GA, Kienhorst LBE, Janssens HJEM, et al. Crystal-proven gout patients have an increased mortality due to cardiovascular diseases, cancer, and infectious diseases especially when having tophi and/or high serum uric acid levels: a prospective cohort study. Clin Rheumatol. 2019;38(5):1385–91. doi:.https://doi.org/10.1007/s10067-019-04520-6
  14. Kyu HH, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al.; GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1859–922. doi:.https://doi.org/10.1016/S0140-6736(18)32335-3
  15. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54(8):2688–96. doi:.https://doi.org/10.1002/art.22014
  16. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63(1):102–10. doi:.https://doi.org/10.1002/acr.20344
  17. Rho YH, Lu N, Peloquin CE, Man A, Zhu Y, Zhang Y, et al. Independent impact of gout on the risk of diabetes mellitus among women and men: a population-based, BMI-matched cohort study. Ann Rheum Dis. 2016;75(1):91–5. doi:.https://doi.org/10.1136/annrheumdis-2014-205827
  18. Kuo C-F, Grainge MJ, Mallen C, Zhang W, Doherty M. Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis. 2016;75(1):210–7. doi:.10.1136/annrheumdis-2014-206410 https://doi.org/10.1136/annrheumdis-2014-206410
  19. Hunter DJ, York M, Chaisson CE, Woods R, Niu J, Zhang Y. Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study. J Rheumatol. 2006;33(7):1341–5.
  20. Rothenbacher D, Primatesta P, Ferreira A, Cea-Soriano L, Rodríguez LAG. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford). 2011;50(5):973–81. doi:.https://doi.org/10.1093/rheumatology/keq363
  21. Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology (Oxford). 2009;48(Suppl 2):ii9–14. doi:.https://doi.org/10.1093/rheumatology/kep087
  22. Kiltz U, Smolen J, Bardin T, Cohen Solal A, Dalbeth N, Doherty M, et al. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis. 2017;76(4):632–8. doi:.https://doi.org/10.1136/annrheumdis-2016-209467
  23. Pascart T, Norberciak L, Ea H-K, Guggenbuhl P, Lioté F. GOSPEL 4 - Patients With Early-Onset Gout and Development of Earlier Severe Joint Involvement and Metabolic Comorbid Conditions: Results From a Cross-Sectional Epidemiologic Survey. Arthritis Care Res (Hoboken). 2019;71(7):986–92.
  24. Janssen CA, Oude Voshaar MAH, Vonkeman HE, Krol M, van de Laar MAFJ. A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands. Clin Rheumatol. 2018;37(8):2291–6. doi:.https://doi.org/10.1007/s10067-018-4127-x
  25. Wright S, Chapman PT, Frampton C, O’Donnell JL, Raja R, Stamp LK. Management of Gout in a Hospital Setting: A Lost Opportunity. J Rheumatol. 2017;44(10):1493–8. doi:.https://doi.org/10.3899/jrheum.170387
  26. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP ; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296. doi:.https://doi.org/10.1371/journal.pmed.0040296
  27. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al.; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4(10):e297. doi:.https://doi.org/10.1371/journal.pmed.0040297
  28. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yü TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20(3):895–900. doi:.https://doi.org/10.1002/art.1780200320
  29. Choi HK, Burns LC, Shojania K, Koenig N, Reid G, Abufayyah M, et al. Dual energy CT in gout: a prospective validation study. Ann Rheum Dis. 2012;71(9):1466–71. doi:.https://doi.org/10.1136/annrheumdis-2011-200976
  30. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3:1–150.
  31. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42. doi:.https://doi.org/10.1136/annrheumdis-2016-209707
  32. Zhao T, Lv X, Cao L, Guo M, Zheng S, Xue Y, et al. Renal excretion is a cause of decreased serum uric acid during acute gout. Int J Rheum Dis. 2018;21(9):1723–7. doi:.https://doi.org/10.1111/1756-185X.13348
  33. Urano W, Yamanaka H, Tsutani H, Nakajima H, Matsuda Y, Taniguchi A, et al. The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J Rheumatol. 2002;29(9):1950–3.
  34. Alvarado-de la Barrera C, López-López CO, Álvarez-Hernández E, Peláez-Ballestas I, Gómez-Ruiz C, Burgos-Vargas R, et al. Are target urate and remission possible in severe gout? A five-year cohort study. J Rheumatol. 2019;181214. doi:.https://doi.org/10.3899/jrheum.181214
  35. Kuo C-F, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015;74(4):661–7. doi:.https://doi.org/10.1136/annrheumdis-2013-204463
  36. Kuo C-F, Grainge MJ, See L-C, Yu K-H, Luo S-F, Zhang W, et al. Epidemiology and management of gout in Taiwan: a nationwide population study. Arthritis Res Ther. 2015;17(1):13. doi:.https://doi.org/10.1186/s13075-015-0522-8
  37. Perez Ruiz F, Sanchez-Piedra CA, Sanchez-Costa JT, Andrés M, Diaz-Torne C, Jimenez-Palop M, et al. Improvement in Diagnosis and Treat-to-Target Management of Hyperuricemia in Gout: Results from the GEMA-2 Transversal Study on Practice. Rheumatol Ther. 2018;5(1):243–53. doi:.https://doi.org/10.1007/s40744-017-0091-1
  38. Lim AY, Shen L, Tan CH, Lateef A, Lau TC, Teng GG. Achieving treat to target in gout: a clinical practice improvement project. Scand J Rheumatol. 2012;41(6):450–7. doi:.https://doi.org/10.3109/03009742.2012.689325
  39. Abhishek A. Managing Gout Flares in the Elderly: Practical Considerations. Drugs Aging. 2017;34(12):873–80. doi:.https://doi.org/10.1007/s40266-017-0512-4
  40. De Vera MA, Marcotte G, Rai S, Galo JS, Bhole V. Medication adherence in gout: a systematic review. Arthritis Care Res (Hoboken). 2014;66(10):1551–9. doi:.https://doi.org/10.1002/acr.22336
  41. Coburn BW, Bendlin KA, Sayles H, Hentzen KS, Hrdy MM, Mikuls TR. Target Serum Urate: Do Gout Patients Know Their Goal? Arthritis Care Res (Hoboken). 2016;68(7):1028–35. doi:.https://doi.org/10.1002/acr.22785
  42. Doherty M, Jenkins W, Richardson H, Sarmanova A, Abhishek A, Ashton D, et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet. 2018;392(10156):1403–12. doi:.https://doi.org/10.1016/S0140-6736(18)32158-5
  43. Stamp LK, O’Donnell JL, Zhang M, James J, Frampton C, Barclay ML, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63(2):412–21. doi:.https://doi.org/10.1002/art.30119
  44. Wason S, Mount D, Faulkner R. Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease. Clin Drug Investig. 2014;34(12):845–55. doi:.https://doi.org/10.1007/s40261-014-0238-6
  45. Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al.; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64(10):1447–61. doi:.https://doi.org/10.1002/acr.21773
  46. Qaseem A, Harris RP, Forciea MA ; Clinical Guidelines Committee of the American College of Physicians. Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017;166(1):58–68. doi:.https://doi.org/10.7326/M16-0570
  47. Rai SK, Choi HK, Choi SHJ, Townsend AF, Shojania K, De Vera MA. Key barriers to gout care: a systematic review and thematic synthesis of qualitative studies. Rheumatology (Oxford). 2018;57(7):1282–92. doi:.https://doi.org/10.1093/rheumatology/kex530

Most read articles by the same author(s)

1 2 3 > >>